Quantitative fetal fibronectin to predict preterm birth in asymptomatic women at high risk.

Obstet Gynecol

Division of Women's Health, King's College London, Women's Health Academic Centre Kings Health Partners, St. Thomas' Hospital, the UCL Institute for Women's Health, the Parturition Research Group, and the Institute for Reproductive and Developmental Biology, Imperial College London, London, the University of Edinburgh MRC Centre for Reproductive Health, Queen's Medical Research Institute, Edinburgh, and West Middlesex University Hospital, Middlesex, United Kingdom; and the Division of Maternal-Fetal Medicine, Loma Linda University Medical Center, Loma Linda, California.

Published: May 2015

Objective: To evaluate the diagnostic accuracy of cervicovaginal fluid quantitative fetal fibronectin, measured by a bedside analyzer, to predict spontaneous preterm birth before 34 weeks of gestation.

Methods: We conducted a prospective masked observational cohort study of cervicovaginal fluid quantitative fetal fibronectin concentration in asymptomatic women at high risk of spontaneous preterm birth (n=1,448; 22-27 6/7 weeks of gestation) measured using a rapid bedside analyzer. The routine qualitative result (positive-negative) was made available to clinicians at the time of testing, but the quantitative result remained blinded until after delivery.

Results: Spontaneous preterm birth (less than 34 weeks of gestation) increased from 2.7%, 11.0%, 14.9%, 33.9%, and 47.6% with increasing concentration of fetal fibronectin (less than 10, 10-49, 50-199, 200-499, and 500 ng/mL or greater, respectively). A threshold of 200 ng/mL had a positive predictive value of 37.7 (95% confidence interval [CI] 26.9-49.4) with specificity 96% (95% CI 95.3-97.3). Women with a fetal fibronectin concentration of less than 10 ng/mL had a very low risk of spontaneous preterm birth at less than 34 weeks of gestation (2.7%), no higher than the background spontaneous preterm birth rate of the general hospital population (3.3%). The quantitative fetal fibronectin test predicted birth at less than 34 weeks of gestation with an area under the curve (AUC) of 0.78 (95% CI 0.73-0.84) compared with the qualitative test AUC 0.68 (95% CI 0.63-0.73). Quantitative fetal fibronectin discriminated risk of spontaneous preterm birth at less than 34 weeks of gestation among women with a short cervix (less than 25 mm); 9.5% delivered prematurely less than 10 ng/mL compared with 55.1% greater than 200 ng/mL (P<.001).

Discussion: Alternative risk thresholds (less than 10 ng/mL and greater than 200 ng/mL) improve accuracy when using quantitative fetal fibronectin measurements to define risk of spontaneous preterm birth. This is particularly relevant for asymptomatic women with a short cervix.

Level Of Evidence: II.

Download full-text PDF

Source
http://dx.doi.org/10.1097/AOG.0000000000000754DOI Listing

Publication Analysis

Top Keywords

fetal fibronectin
28
preterm birth
28
spontaneous preterm
24
quantitative fetal
20
birth weeks
20
weeks gestation
20
risk spontaneous
12
birth
8
asymptomatic women
8
women high
8

Similar Publications

Preeclampsia (PE) is a gestational complication affecting 5% to 10% of all pregnancies. PE is characterized by hypertension and endothelial dysfunction, whose etiology involves, among other factors, alterations in the extracellular matrix (ECM) that can compromise vascular remodeling and trophoblast invasion, ie, processes essential for placental development. Endothelial dysfunction is caused by release of antiangiogenic factors, mainly a soluble fms-like tyrosine kinase-1 (sFlt-1), which antagonizes two endothelial angiogenic factors, the vascular endothelial growth factor (VEGF) and placental growth factor (PLGF).

View Article and Find Full Text PDF
Article Synopsis
  • Preeclampsia is a condition with serious risks for mothers and babies, and new angiogenic markers are being used to help diagnose it quickly in clinical settings.
  • The study analyzed the effectiveness of various point-of-care tests for predicting preeclampsia, focusing on their sensitivity and specificity based on data from 17 relevant studies.
  • Glycosylated fibronectin testing showed promising results with a sensitivity of 0.80 and specificity of 0.84, indicating it could be a valuable tool for clinical decisions regarding preeclampsia in high-risk patients.
View Article and Find Full Text PDF

Objectives: To evaluate glycosylated fibronectin (GlyFn) as a novel biomarker for preeclampsia and preeclampsia-related complications, and to compare GlyFn to traditional biomarkers, including soluble Fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF).

Study Design: Secondary analysis of a prospective cohort study (n = 524) with suspected preeclampsia (control), gestational hypertension (GH), or confirmed preeclampsia/hemolysis, elevated liver enzymes and low platelets syndrome (PE/HELLP).

Main Outcome Measures: GlyFn levels in PE/HELLP versus control and GH.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!